A panel consisting of Steven Lee of Kenyon & Kenyon LLP, Michael Perry of the Health Care Division of the Bureau of Competition at the Federal Trade Commission, and Bruce Wexler of Paul Hastings LLP will discuss the valuation of reverse payments in general, the role of ancillary agreements such as joint marketing agreements, and whether a branded company's promise not to launch an authorized generic during the generic’s exclusivity period amounts to a reverse... [read post]